Physician profile
Robert S Hoffman
NPI 1780841536
$7,667.36
in general payments reported to CMS, 2019-2025
27 companies · $817 in 2025
The $817 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $894 · 2020: $1,195 · 2021: $3,070 · 2022: $469 · 2023: $440 · 2024: $782 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,027 · Education: $11.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,027.10 |
| Education | $11.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $2,194.36 | 2020-2022 | |
| Allergan, INC. | $708.45 | 2019-2020 | |
| Abbvie INC. | $672.69 | 2021-2025 | |
| Bausch Health US, LLC | $621.65 | 2019-2025 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $547.39 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $458.93 | 2019-2025 | Fanapt |
| Lundbeck LLC | $282.54 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $261.58 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $250.09 | 2023-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $212.57 | 2020-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $205.25 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $178.13 | 2021-2024 | Caplyta |
| Alkermes, INC. | $144.04 | 2020-2025 | Aristada, Lybalvi |
| Merck Sharp & Dohme LLC | $134.89 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $118.79 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $104.70 | 2024 | Loreev Xr |
| Avanir Pharmaceuticals, INC. | $104.24 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.29 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $62.63 | 2021 | |
| Ironshore Pharmaceuticals INC. | $60.60 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $55.36 | 2023-2025 | Quviviq, Quviviq |
| Adlon Therapeutics L.P. | $55.35 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $41.08 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $34.84 | 2019-2020 | |
| Noven Therapeutics, LLC | $23.75 | 2020 | |
| Assertio Therapeutics, INC. | $18.87 | 2020 | |
| Neurocrine Biosciences, INC. | $14.30 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.